CellMax Life Leads Liquid Biopsy Discussion with Chief Medical Officer of ASCO and Industry Leaders at 2018 Precision Medicine World Conference

Share Article

Leading cancer diagnostics company highlights innovation in detecting circulating tumor cells for early cancer detection at less than $150

News Image

Atul Sharan, CEO of CellMax Life, a leading cancer diagnostics company, today led a panel discussion at the 2018 Precision Medicine World Conference (PMWC) on the clinical utility of liquid biopsies with other oncology thought leaders including Dr. Richard Schilsky, senior vice president and chief medical officer of The American Society of Clinical Oncology (ASCO); Dr. Bruce Patterson, CEO and founder of IncellDx; and Yatin Mundkur, CEO of Cellworks.

The panelists discussed the advantages of circulating tumor cells (CTCs) in enabling multi-biomarker analysis (DNA, RNA, protein expression) and in overcoming tumor heterogeneity with analysis of samples at the single cell level.

Also at PMWC, Sharan showcased CellMax Life's proprietary CTC blood test for the capture of circulating tumor cells. CTCs are cancer cells that detach from a primary tumor and circulate through the bloodstream and are a fundamental mechanism of metastasis. CTCs have long been known to be valuable in cancer detection, but most technologies testing for CTCs are only able to detect late-stage cancer. The CellMax CTC "liquid biopsy" blood test detects these CTCs in the blood at the earliest, most treatable stages.

Once captured, these cells can be analyzed downstream for multiple therapy selection biomarkers including protein expression (PD-L1, AR-V7) and DNA based markers (EGFR, ERRB2/ HER2) using next generation sequencing and methylation markers.

These sessions follow a podium presentation at ASCO's gastro-intestinal conference held last week in San Francisco on a 620-patient study that showed that the CellMax CTC blood test detected early stage colorectal cancer and pre-cancer with an accuracy ranging from 84 to 88 percent.

"Early detection is perhaps the only real cure for cancer. To be effective, tests for early cancer detection need to be non-invasive, easy, highly affordable and accurate. The CellMax CTC blood test meets all of these requirements," said Atul Sharan, co-founder and CEO of CellMax Life. "With the use of tumor specific antibodies, the CTC blood test can identify the origin of major solid tumors. It is therefore a pan-cancer platform for cancer detection, therapy selection, and treatment effectiveness monitoring."

PMWC is recognized as the leading annual forum on precision medicine, delivering the most current and up-to-date content across all facets of personalized and precision medicine. The conference attracts over 11,000 attendees and includes presentations and panels made by the world's leading authorities and experts across the healthcare and bioinformatics sectors.

About CellMax Life
CellMax Life is a leading cancer diagnostics company whose mission is to transform how cancer is diagnosed and managed with globally affordable non-invasive tests for early cancer detection and management. CellMax Life's unique expertise in circulating tumor cells (CTC) and next generation sequencing (NGS) of DNA, as well as circulating tumor DNA (ctDNA) has enabled highly effective precision medicine solutions for healthy people, as well as patients diagnosed with cancer.

CellMax Life's tests include CellMax-DNA Hereditary Cancer Risk Test, CellMax-CRC Colorectal Cancer Screening Test, CellMax-Prostate Cancer Test, CellMax-LBx Liquid Biopsy for immunotherapy and targeted therapy selection and CellMax-PanCa Monitoring Test. All clinical testing is performed at CLIA and CAP accredited laboratories in Sunnyvale, California and Taipei, Taiwan.

For additional information, please visit http://www.cellmaxlife.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mike Simmons
Antenna Group
+1 (714) 504 7932
Email >
Visit website